enGene Therapeutics (ENGN) vs Fate Therapeutics (FATE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Fate Therapeutics (FATE) has outperformed enGene Therapeutics (ENGN) over the past year, losing 10.8% versus a loss of 75.0%. enGene Therapeutics is the larger company by market cap ($116.6 million vs $111.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENGN | FATE |
|---|---|---|
| Share price | $1.74 | $0.919 |
| Market cap | $116.61M | $111.82M |
| 1-day change | -1.14% | -9.01% |
| YTD return | -80.73% | -6.22% |
| 1-year return | -75.00% | -10.78% |
| 5-year return | — | -98.25% |
| EPS (TTM) | $-2.07 | $-1.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $6.65M |
| Revenue growth (YoY) | — | -51.24% |
| Net income (latest FY) | $-117.30M | $-136.31M |
| Operating margin | — | -2222.45% |
| Net margin | — | -2051.08% |
| 52-week high | $12.25 | $3.23 |
| 52-week low | $1.40 | $0.90 |
| Distance from 52-week high | -85.80% | -71.55% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +146.55% | +522.42% |
| Average volume | 1.12M | 1.53M |
| Shares outstanding | 67.02M | 121.67M |
| Employees | 81 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FATE has outperformed ENGN by 64.2 percentage points over the past year.
About enGene Therapeutics
ENGN stock →enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About Fate Therapeutics
FATE stock →Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees
ENGN vs FATE FAQ
Which is bigger, enGene Therapeutics or Fate Therapeutics?
enGene Therapeutics (ENGN) is larger, with a market capitalization of $116.61M compared with $111.82M for Fate Therapeutics (FATE).
Which stock has performed better over the past year, ENGN or FATE?
FATE returned -10.78% over the past 12 months, compared with -75.00% for ENGN (price return, excluding dividends). Past performance does not predict future results.
Are enGene Therapeutics and Fate Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.